title: Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
abstract: The aim of this study was to evaluate the clinical value of assessing epidermal growth factor receptor (EGFR) amplification and the common 5' rearrangement of EGFR resulting in the EGFRvIII transcript in astrocytic gliomas. Data from 221 tumours were correlated with patient survival. The majority of previous studies evaluated amplification alone and provided contradictory results. Amplification was analysed by a densitometry of Southern blot analysis or quantitative polymerase chain reaction (PCR). EGFR transcripts were examined by reverse transcription PCR and subsequent sequencing. A ribonuclease (RNase) protection assay was carried out on a subgroup to confirm PCR results. Amplification of EGFR was found in 41% (65/160) of glioblastomas (GBs) and 10% (4/41) of anaplastic astrocytomas (AAs). The EGFRvIII rearrangement was identified in 54% (35/65) of GBs and 75% (3/4) of AAs with amplification, as well as in 8% (8/95) of GBs and 5% (2/37) of AAs without amplification (confirmed by RNase protection assay). There were no abnormalities of the EFGR or its transcript in grade II astrocytoma (AII). We found no significant association between EGFR amplification or rearrangement, and age or survival in the 160 GB patients. We noted a tendency towards decreased survival with any EGFR abnormality in the 41 patients with AAs. This was most marked in the five cases with the EGFRvIII transcript (p=0.069), but these were significantly older than those without (p=0.023). No abnormalities of EGFR were identified in AII patients. We conclude that neither EGFR amplification nor the presence of the EGFRvIII transcript predicts patient outcome in conventionally treated GBs. However, in AAs, although uncommon, EGFR aberrations appear to be associated with shorter survival.
authors.affiliation: Division of Molecular Histopathology, Department of Pathology, Addenbrooke's Hospital, University of Cambridge, P.O.Box 231, Cambridge, CB2 2QQ, UK.
authors.forename: Lu
authors.initials: L
authors.lastname: Liu
authors.forename: L Magnus
authors.initials: LM
authors.lastname: Bäcklund
authors.forename: Bo R
authors.initials: BR
authors.lastname: Nilsson
authors.forename: Dan
authors.initials: D
authors.lastname: Grandér
authors.forename: Koichi
authors.initials: K
authors.lastname: Ichimura
authors.forename: Helena M
authors.initials: HM
authors.lastname: Goike
authors.forename: V Peter
authors.initials: VP
authors.lastname: Collins
mesh_terms: D000328:Adult; D000367:Age Factors; D001254:Astrocytoma / Q000235:genetics*; D015415:Biomarkers / Q000032:analysis; D016543:Central Nervous System Neoplasms / Q000235:genetics*; D066246:ErbB Receptors / Q000032:analysis / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D018628:Gene Dosage; D005909:Glioblastoma / Q000235:genetics*; D005910:Glioma / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D016019:Survival Analysis
chemical_list: D015415:Biomarkers; C410723:epidermal growth factor receptor VIII; D066246:ErbB Receptors